FDA Approves Cemiplimab-rwlc for Cutaneous Squamous Cell Carcinoma

On September 28, the U.S. Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Sanofi) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

Read the full FDA press release here.

Posted 10/1/18